Home › Esperion Announces Positive Topline Results from a Phase 2 Clinical...
 

Keywords :   


Esperion Announces Positive Topline Results from a Phase 2 Clinical...

2013-01-08 02:44:31| Biotech - Topix.net

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

Tags: results positive phase clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Hurricane Milton Public Advisory Number 5A
06.10Summary for Hurricane Milton (AT4/AL142024)
06.10Atlantic Tropical Weather Outlook
06.10Eastern North Pacific Tropical Weather Outlook
06.10Glatfelter Develops Biobased Espresso Lid Material
06.10Tropical Storm Milton Potential Storm Surge Flooding Map
06.10Tropical Storm Milton Probabilistic Storm Surge Graphics
06.10Firms urge mayor to rethink congestion charge plan
More »